M35 is a peptide antagonist at galanin receptors that exhibits antidepressant and insulin-modulating activities. In the forced swim test, M35 decreases immobility time. M35 displays neuroprotective and cognition enhancing activities as well, improving acquisition time, decreasing the number of failed trials, and shortening escape latency in rodents undergoing the forced swim test, an animal model of spatial learning. M35 also suppresses pancreatitis-induced plasma hyperenzymemia and decreases myeloperoxidase activity, decreasing necrosis. Additionally, M35 decreases glucose uptake, PPARα expression, and membrane GLUT4 levels, attenuating insulin sensitivity in other animal models.